Business and Finance

Eton Pharmaceuticals reached its long-held goal of ten rare disease commercial products, acquiring the US rights to Hemangeol, the only FDA-approved treatment for infantile hemangioma.

SpotSee and Controlant announced a collaboration to enhance pharmaceutical supply chain visibility using integrated monitoring devices and cloud-based indicators.

In today’s Pharma Pulse, the FDA grants priority review to a therapy for polycythemia vera, while Novo Nordisk receives expanded pediatric approval for its once-weekly growth hormone.

In today’s Pharma Pulse, the FDA grants a lightning-fast approval for Boehringer’s lung cancer therapy under its new priority program, while CMS Administrator Mehmet Oz launches a sweeping offensive against fraudulent billing.

The FDA granted accelerated approval to Boehringer Ingelheim’s Hernexeos for first-line HER2-mutant NSCLC following a 44-day review under the National Priority Voucher Program.

A guide to how the IRA is reshaping Medicare Part D, price negotiations, manufacturer liability, and pharmacy operations, along with what it means for access, adherence, and commercial strategy.

Dan Chancellor, Norstella's vice president of thought leadership, examines how the patent cliff and persistent growth gaps are shaping pharma M&A strategy heading into 2026.

In today’s Pharma Pulse, Eli Lilly’s orforglipron shows superior blood sugar control over oral semaglutide, while GSK secures a $950 million acquisition of 35Pharma.

CMS’s CY 2027 Medicare Advantage rates signal mounting cost pressure, setting the stage for tighter benefits, tougher contracting, and heightened access scrutiny in the months ahead.

In today’s Pharma Pulse, UK regulators seize thousands of fake weight loss pens, while new data reveals that the "miracle jab" is financially out of reach for nearly 70% of users.

In the final part of his Pharma Commerce video interview, John Stanford, Incubate’s executive director, argues that while Medicare price controls may reduce federal spending, they have yet to meaningfully improve patient access—contending that true reform must address insurance design, out-of-pocket costs, and the long-term impact on life sciences innovation and investment.

In today’s Pharma Pulse, the FDA unveils a Plausible Mechanism framework to fast-track ultra-rare disease therapies, while Astellas partners with Vir Biotechnology in a massive $2.1 billion oncology collaboration.

In the third part of his Pharma Commerce video interview, John Stanford, Incubate’s executive director, shares how Incubate’s analysis of SEC filings reports dozens of halted research programs following the Inflation Reduction Act’s passage, while recent legislative changes tied to orphan drugs appear to be influencing renewed rare disease investment.

In the second part of his Pharma Commerce video interview, John Stanford, Incubate’s executive director, points out how uneven Medicare negotiation timelines between small molecules and biologics are influencing R&D and venture funding decisions, according to biotech investors advocating for legislative changes.

A policy change allowing approval of some new drugs based on one adequate and well-controlled study could accelerate development timelines, while raising questions about evidentiary standards and downstream supply chain planning.

The logistics provider has launched a temperature-controlled network with new dedicated capacity and aviation routes designed to enhance the transport of time-critical pharmaceuticals and biologics, responding to the rising demand for reliable, compliant cold-chain logistics.

In the first part of his Pharma Commerce video interview, John Stanford, Incubate’s executive director, explains how third round of CMS drug selections brings physician-administered medicines under price controls for the first time, intensifying debate over provider reimbursement and investment in small-molecule therapies.

The online pharmacy is collaborating with a digital health provider to combine direct-to-patient GLP-1 dispensing with virtual clinical support, highlighting evolving supply chain and regulatory considerations in obesity care.

In the final part of his Pharma Commerce video interview, Dan Chancellor, Norstella’s vice president of thought leadership, shares that companies facing the largest revenue gaps from looming patent expirations—including Bristol Myers Squibb—could be poised for increased dealmaking as they look to rebuild growth pipelines.

A 2026 industry survey finds mounting pressure from PBMs, federal pricing reforms, and compliance scrutiny, as manufacturers increase automation and AI investment to manage expanding gross-to-net exposure.

In the second part of his Pharma Commerce video interview, Dan Chancellor, Norstella’s vice president of thought leadership, suggests that 2026 pharma M&A may fall short of last year’s $220 billion total—potentially featuring fewer but larger, high-value acquisitions driven by competitive bidding.

In the first part of his Pharma Commerce video interview, Dan Chancellor, Norstella’s vice president of thought leadership, explains that despite a looming loss of exclusivity affecting up to $300 billion in drug sales by 2032, pharma dealmaking is expected to remain steady in 2026, as companies pursue acquisitions to close persistent portfolio growth gaps.

The new platform offers coupon-driven discounts on dozens of high-cost brand name drugs, while raising new questions about eligibility, access, and how savings are applied.

A landmark FTC settlement requires Express Scripts to overhaul formulary and rebate practices, boosting price transparency in the process.

The acquisition expands ORBIS’ manufacturing capacity and technical expertise in reusable plastic pallets, lids, and trays, enabling faster design, prototyping, and production for pharma and broader supply chain applications.